MCID: MXD023
MIFTS: 44

Mixed Cell Type Cancer

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Mixed Cell Type Cancer

MalaCards integrated aliases for Mixed Cell Type Cancer:

Name: Mixed Cell Type Cancer 12 15 17
Malignant Mixed Neoplasm 12 17
Mixed Tumor, Malignant 12 44
Malignant Mixed Tumor 12 70
Mixed Neoplasm 12 70
Malignant Mixed Tumor, Not Otherwise Specified 70
Mixed Tumor, Not Otherwise Specified 70
Mixed Salivary Gland Tumor 70
Malignant Mixed Cancer 12
Mixed Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:154
MeSH 44 D018198
NCIt 50 C3729 C6930
SNOMED-CT 67 8145008
UMLS 70 C0026277 C0206625 C1368354 more

Summaries for Mixed Cell Type Cancer

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from two germinal layers of tissue.

MalaCards based summary : Mixed Cell Type Cancer, also known as malignant mixed neoplasm, is related to ovarian carcinosarcoma and uterine corpus adenosarcoma. An important gene associated with Mixed Cell Type Cancer is SERPINA3 (Serpin Family A Member 3), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Gemcitabine and Topotecan have been mentioned in the context of this disorder. Affiliated tissues include uterus, salivary gland and ovary, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Mixed Cell Type Cancer

Diseases related to Mixed Cell Type Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 742)
# Related Disease Score Top Affiliating Genes
1 ovarian carcinosarcoma 32.2 TP53 PIK3CA H2AC18 ERBB2 ARID1A
2 uterine corpus adenosarcoma 32.1 PGR MME ESR1
3 adenomyoma 31.9 PGR MME KRT7 CTNNB1
4 uterine body mixed cancer 31.4 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
5 pleomorphic adenoma 31.3 TP53 KRT7 HRAS ERBB2 CTNNB1
6 wilms tumor 1 31.0 TP53 SERPINA3 PGR MME KRT7 KRAS
7 carcinosarcoma 30.9 TP53 PTEN PPP2R1A PIK3CA PGR MME
8 skin benign neoplasm 30.8 SERPINA3 KRT7 KRT5 HRAS
9 adenoma 30.6 TP53 SYP PIK3CA KRT7 KRAS CTNNB1
10 leiomyosarcoma 30.5 TP53 SERPINA3 PGR KIT ESR1
11 adenofibroma 30.5 TP53 MME KRT7 ARID1A
12 basaloid squamous cell carcinoma 30.4 TP53 SYP KRT7
13 spindle cell sarcoma 30.4 SERPINA3 KRT7 KIT
14 lipomatosis, multiple 30.3 SERPINA3 PTEN KIT
15 epithelial-myoepithelial carcinoma 30.3 TP53 PIK3CA KRT7 HRAS
16 myoepithelial carcinoma 30.3 TP53 PIK3CA KRT7 HRAS
17 pleomorphic rhabdomyosarcoma 30.3 TP53 SYP MME KRT7
18 mesenchymal cell neoplasm 30.3 TP53 SERPINA3 MME KIT
19 thymoma 30.3 TP53 SYP KIT HRAS
20 liposarcoma 30.3 TP53 PTEN PIK3CA CTNNB1
21 ameloblastoma 30.3 TP53 SERPINA3 KRAS CTNNB1
22 appendix adenocarcinoma 30.2 SYP KRT7 KRAS HRAS
23 hidradenoma 30.2 PIK3CA MME KRT7 KRT5
24 ceruminoma 30.2 KRT7 KRT5
25 cystadenoma 30.2 SYP SERPINA3 PTEN PGR MME KRT7
26 necrotizing sialometaplasia 30.2 TP53 KRT7 KRT5
27 exanthem 30.1 KRAS KIT HRAS H2AC18 ERBB2
28 krukenberg carcinoma 30.1 SYP KRT7
29 benign teratoma 30.1 TP53 SYP KRT7
30 transitional cell carcinoma 30.1 TP53 PTEN KRT7 HRAS ERBB2 CDH1
31 hepatoblastoma 30.1 TP53 SERPINA3 KRT7 CTNNB1 CDH1
32 well-differentiated liposarcoma 30.1 TP53 SERPINA3 KRT7 KIT
33 pheochromocytoma 30.0 SYP MME KRT7 KIT HRAS ESR1
34 ovarian serous carcinoma 30.0 TP53 KRAS CDH1
35 breast fibroadenoma 30.0 TP53 SERPINA3 PGR MME LCOR ESR1
36 neuroendocrine carcinoma 30.0 SYP PTEN KRT7 KIT CDH1
37 embryonal sarcoma 30.0 TP53 SERPINA3 KIT CTNNB1
38 cystic teratoma 30.0 TP53 SYP PTEN KRT7 KRAS KIT
39 sarcoma 29.9 TP53 PIK3CA KRAS KIT HRAS CTNNB1
40 chordoma 29.9 TP53 SERPINA3 PTEN KRT7 CDH1
41 mammary paget's disease 29.9 PGR LCOR KRT7 ESR1 ERBB2
42 neurofibroma 29.9 TP53 SYP PTEN KIT ERBB2
43 apocrine sweat gland neoplasm 29.8 PGR KRT7 KRT5 ESR1 ERBB2
44 mucinous adenocarcinoma 29.8 TP53 PGR KRT7 KRAS KIT ESR1
45 mucoepidermoid carcinoma 29.8 TP53 SERPINA3 KRT7 KRT5 ERBB2 CTNNB1
46 papilloma 29.8 TP53 PTEN KRT7 KRT5 KRAS ERBB2
47 teratoma 29.7 TP53 SYP PTEN KRT7 KRAS KIT
48 sarcoma, synovial 29.7 SERPINA3 KRT7 KIT H2AC18 CTNNB1 CDH1
49 hemangioma 29.7 TP53 SYP PTEN PGR KRT7 KRAS
50 mature teratoma 29.7 TP53 SYP KRT7 KRAS KIT H2AC18

Graphical network of the top 20 diseases related to Mixed Cell Type Cancer:



Diseases related to Mixed Cell Type Cancer

Symptoms & Phenotypes for Mixed Cell Type Cancer

GenomeRNAi Phenotypes related to Mixed Cell Type Cancer according to GeneCards Suite gene sharing:

26 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.32 HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.32 HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.32 KRAS
4 Decreased viability GR00106-A-0 10.32 KRAS
5 Decreased viability GR00221-A-1 10.32 CDH1 ESR1 HRAS KIT KRAS PIK3CA
6 Decreased viability GR00221-A-2 10.32 ESR1 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.32 HRAS
8 Decreased viability GR00221-A-4 10.32 ESR1 PIK3CA
9 Decreased viability GR00301-A 10.32 CDH1 KIT KRAS
10 Decreased viability GR00381-A-1 10.32 KRAS
11 Decreased viability GR00386-A-1 10.32 ESR1
12 Decreased viability GR00402-S-2 10.32 CDH1 ESR1 PIK3CA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.78 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.78 PTEN
15 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.78 PTEN
16 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.78 ERBB2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.78 ARID1A ERBB2 PTEN
18 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.78 ARID1A
19 Increased shRNA abundance (Z-score > 2) GR00366-A-186 9.78 ARID1A
20 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.78 ARID1A
21 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.78 ERBB2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.78 ARID1A
23 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.78 PTEN
24 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.78 KRAS
25 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.78 ERBB2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.78 PTEN
27 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.78 ARID1A
28 Increased shRNA abundance (Z-score > 2) GR00366-A-60 9.78 ERBB2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.78 ERBB2 KRAS PTEN
30 Increased shRNA abundance (Z-score > 2) GR00366-A-66 9.78 PTEN
31 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.78 ARID1A
32 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.78 H2AC18
33 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.78 ERBB2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-87 9.78 ERBB2 PTEN
35 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.78 PTEN
36 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.78 H2AC18
37 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.65 CTNNB1

MGI Mouse Phenotypes related to Mixed Cell Type Cancer:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.47 CTNNB1 ERBB2 ESR1 HRAS KIT KRAS
2 homeostasis/metabolism MP:0005376 10.44 ARID1A CDH1 CTNNB1 ERBB2 ESR1 HRAS
3 cardiovascular system MP:0005385 10.4 ARID1A CDH1 CTNNB1 ERBB2 ESR1 HRAS
4 cellular MP:0005384 10.4 ARID1A CDH1 CTNNB1 ERBB2 ESR1 KIT
5 integument MP:0010771 10.36 CDH1 CTNNB1 ERBB2 ESR1 HRAS KIT
6 mortality/aging MP:0010768 10.35 ARID1A CDH1 CTNNB1 ERBB2 ESR1 HRAS
7 endocrine/exocrine gland MP:0005379 10.33 ARID1A CDH1 CTNNB1 ERBB2 ESR1 HRAS
8 embryo MP:0005380 10.3 ARID1A CDH1 CTNNB1 ERBB2 ESR1 KIT
9 immune system MP:0005387 10.3 ARID1A CDH1 CTNNB1 ESR1 KIT KRAS
10 digestive/alimentary MP:0005381 10.27 CDH1 CTNNB1 ERBB2 ESR1 HRAS KIT
11 neoplasm MP:0002006 10.25 ARID1A CDH1 CTNNB1 ERBB2 ESR1 HRAS
12 muscle MP:0005369 10.2 ARID1A CTNNB1 ERBB2 ESR1 HRAS KIT
13 craniofacial MP:0005382 10.18 ARID1A CTNNB1 ERBB2 HRAS KIT KRAS
14 nervous system MP:0003631 10.18 ARID1A CTNNB1 ERBB2 ESR1 HRAS KIT
15 limbs/digits/tail MP:0005371 10.15 CTNNB1 ERBB2 ESR1 KIT KRAS KRT5
16 normal MP:0002873 10.13 ARID1A CDH1 CTNNB1 ERBB2 ESR1 HRAS
17 no phenotypic analysis MP:0003012 10.07 ARID1A CDH1 CTNNB1 ESR1 HRAS KIT
18 reproductive system MP:0005389 9.9 ARID1A CDH1 CTNNB1 ERBB2 ESR1 KIT
19 renal/urinary system MP:0005367 9.86 CTNNB1 ESR1 HRAS KIT KRAS KRT7
20 respiratory system MP:0005388 9.56 CTNNB1 ERBB2 ESR1 HRAS KIT KRAS
21 skeleton MP:0005390 9.36 ARID1A CTNNB1 ERBB2 ESR1 HRAS KIT

Drugs & Therapeutics for Mixed Cell Type Cancer

Drugs for Mixed Cell Type Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
2
Topotecan Approved, Investigational Phase 2, Phase 3 123948-87-8, 119413-54-6 60700
3
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
4
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
5
Ifosfamide Approved Phase 3 3778-73-2 3690
6
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
9
Liposomal doxorubicin Phase 2, Phase 3 31703
10 Alkylating Agents Phase 3
11
Isophosphamide mustard Phase 3 100427
12
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
13
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
14
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
15
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
16
Bevacizumab Approved, Investigational Phase 2 216974-75-3
17
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
18
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 43805 6857599
19
Mesna Approved, Investigational Phase 2 3375-50-6 598
20
Thalidomide Approved, Investigational, Withdrawn Phase 2 50-35-1 5426
21
Olaparib Approved Phase 2 763113-22-0 23725625
22
Iodine Approved, Investigational Phase 2 7553-56-2 807
23
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
24
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
25
Metformin Approved Phase 2 657-24-9 4091 14219
26
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
27
Durvalumab Approved, Investigational Phase 2 1428935-60-7
28
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
29
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
30
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
31
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
32
Sirolimus Approved, Investigational Phase 2 53123-88-9 6436030 5284616
33
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
34
Iniparib Investigational Phase 2 160003-66-7
35
Cediranib Investigational Phase 2 288383-20-0 9933475
36
MK-1775 Investigational Phase 2 955365-80-7, 501-36-0 24856436 445154
37
Entinostat Investigational Phase 1, Phase 2 209783-80-2
38
Tremelimumab Investigational Phase 2 745013-59-6
39 Tubulin Modulators Phase 2
40 Antimitotic Agents Phase 2
41 Albumin-Bound Paclitaxel Phase 2
42 Angiogenesis Inhibitors Phase 2
43 Imatinib Mesylate Phase 2 220127-57-1 123596
44 Epothilones Phase 2
45 Epothilone B Phase 2
46 Liver Extracts Phase 2
47
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
48 Pharmaceutical Solutions Phase 2
49 Tin Fluorides Phase 2
50 Protein Kinase Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 55)
# Name Status NCT ID Phase Drugs
1 A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy Recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
2 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
3 A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
4 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
5 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
6 A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
7 A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma Completed NCT00238121 Phase 2 sorafenib tosylate
8 A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
9 A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas Completed NCT00390234 Phase 2 ziv-aflibercept
10 A Pilot Phase II Trial of Adjuvant Radiation Therapy "Sandwiched" Between Ifosfamide in Patients With Mixed Mesodermal Tumors Completed NCT00231842 Phase 2 Ifosfamide;Cisplatin
11 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
12 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
13 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01168232 Phase 2 Ixabepilone
14 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
15 Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
16 A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
17 A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
18 Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
19 A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma Recruiting NCT03458728 Phase 1, Phase 2 BAY806946
20 An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
21 A 3-Arm Randomised Phase II Evaluation of Cediranib in Combination With Weekly Paclitaxel or Olaparib Versus Weekly Paclitaxel Chemotherapy for Advanced Endometrial Carcinoma or for Disease Relapse Within 18 Months of Adjuvant Carboplatin-paclitaxel Chemotherapy. Recruiting NCT03570437 Phase 2 Paclitaxel;Cediranib;Olaparib
22 A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Recruiting NCT03668340 Phase 2 AZD1775
23 A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated With Pamiparib in Subjects With Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma Who Have Progressed on P-gp Substrate Chemotherapy or PARPi With the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion Recruiting NCT03933761 Phase 2 Pamiparib
24 MC1365, A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer Recruiting NCT02364713 Phase 2 Gemcitabine Hydrochloride;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
25 A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers Recruiting NCT03924245 Phase 1, Phase 2 Entinostat;Olaparib
26 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
27 An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma Recruiting NCT03694262 Phase 2 Rucaparib;Bevacizumab;Atezolizumab
28 A Phase 2 Trial of ZW25 in HER2 Overexpressed Advanced Endometrial Cancers and Carcinosarcomas (ZW25-IST-2) Recruiting NCT04513665 Phase 2 ZW25
29 A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline
30 A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056) Recruiting NCT04106414 Phase 2 Nivolumab;BMS- 986205
31 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Recruiting NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
32 A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma Active, not recruiting NCT03015129 Phase 2 Durvalumab;Tremelimumab
33 Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS) Active, not recruiting NCT02993705 Phase 2 Trabectedin
34 A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial, Epithelial Ovarian Cancer, or Carcinosarcoma Active, not recruiting NCT03395080 Phase 2 Paclitaxel;300mg DKN-01;600mg DKN-01
35 A Phase II Study of Adjuvant Postoperative Radiation With Cisplatin Followed by Carboplatin/Paclitaxel Chemotherapy Following Total Abdominal Hysterectomy/Bilateral Salpino-Oophorectomy (TAH/BSO) for Patients With Stage I, II and IIIa Malignant Mixed Mesodermal Tumor (MMMT) of the Uterus. Terminated NCT00505492 Phase 2 Carboplatin;Cisplatin;Paclitaxel
36 Pilot Phase II Study of Temsirolimus in Patients With Recurrent Mixed Mesodermal and Mullerian Tumors (Carcinosarcoma) of the Uterus Terminated NCT01061606 Phase 2 temsirolimus
37 A Phase II Study of Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer Terminated NCT00322881 Phase 2 Paclitaxel;Carboplatin
38 A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma Terminated NCT03509207 Phase 2 Vorinostat Oral Capsule
39 A Phase II Single Arm Study of Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma Withdrawn NCT04149275 Phase 2 Cabozantinib;Ipilimumab;Nivolumab
40 A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma Unknown status NCT01454479 Phase 1 Lapatinib and ixempra
41 A Phase I Trial of Dose Dense (Biweekly) Carboplatin Combined With Paclitaxel and Pegfilgrastim (Neulasta): A Feasibility Study in Patients With Untreated Stage III and IV Ovarian, Tubal or Primary Peritoneal Cancer Completed NCT00352300 Phase 1 Carboplatin;Paclitaxel
42 Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Recruiting NCT03552471 Phase 1 Rucaparib Camsylate
43 Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary Recruiting NCT03206177 Phase 1 Galunisertib;Paclitaxel;Carboplatin
44 A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
45 Targeted Complex Therapy for Advanced Melanoma, Gynecologic Cancers, and Other Malignancies: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex) Suspended NCT02020707 Phase 1 Nab-paclitaxel
46 microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer Unknown status NCT02964351
47 A Pilot Study to Assess the Suitability of DCE-MRI for Detection of Vascular Changes After Vaginal Brachytherapy Completed NCT01991808
48 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors - A Randomized Controlled Trial Recruiting NCT03641287
49 GISAR German Interdisciplinary Sarcoma Registry Recruiting NCT04122872
50 Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial Cancer Active, not recruiting NCT01737619 Indocyanine Green Solution

Search NIH Clinical Center for Mixed Cell Type Cancer

Cochrane evidence based reviews: mixed tumor, malignant

Genetic Tests for Mixed Cell Type Cancer

Anatomical Context for Mixed Cell Type Cancer

MalaCards organs/tissues related to Mixed Cell Type Cancer:

40
Uterus, Salivary Gland, Ovary, Lymph Node, Liver, Skin, Prostate

Publications for Mixed Cell Type Cancer

Articles related to Mixed Cell Type Cancer:

# Title Authors PMID Year
1
Malignant mixed tumor (malignant ameloblastoma and fibrosarcoma) of the maxilla. 61
1987921 1991
2
[On three cases of rare big tumor on palate benign mixed tumor, malignant mixed tumor, and lymphosarcoma]. 61
5252867 1968

Variations for Mixed Cell Type Cancer

Expression for Mixed Cell Type Cancer

Search GEO for disease gene expression data for Mixed Cell Type Cancer.

Pathways for Mixed Cell Type Cancer

Pathways related to Mixed Cell Type Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 81)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.23 TP53 PTEN PPP2R1A PIK3CA PGR KRAS
2
Show member pathways
14.08 TP53 SERPINA3 PTEN PPP2R1A PIK3CA MME
3
Show member pathways
13.87 TP53 PTEN PPP2R1A KRAS KIT HRAS
4
Show member pathways
13.6 TP53 PPP2R1A PIK3CA KRAS KIT HRAS
5
Show member pathways
13.55 PPP2R1A PIK3CA KRT7 KRT5 KRAS KIT
6
Show member pathways
13.5 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
7
Show member pathways
13.41 TP53 PPP2R1A PIK3CA KRAS KIT HRAS
8
Show member pathways
13.35 PTEN KRAS KIT HRAS ERBB2 CTNNB1
9
Show member pathways
13.33 PPP2R1A KRAS KIT HRAS ESR1 ERBB2
10
Show member pathways
13.03 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
11
Show member pathways
12.98 PTEN PPP2R1A KRAS HRAS CTNNB1 CDH1
12
Show member pathways
12.95 PTEN PIK3CA KRAS HRAS ERBB2 CTNNB1
13 12.81 TP53 KRAS KIT HRAS ERBB2
14
Show member pathways
12.8 PIK3CA KRAS KIT HRAS CTNNB1 CDH1
15
Show member pathways
12.8 TP53 PTEN PIK3CA KRAS KIT HRAS
16
Show member pathways
12.77 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
17
Show member pathways
12.72 PIK3CA PGR KRAS HRAS ESR1
18
Show member pathways
12.69 TP53 PTEN PIK3CA KRAS HRAS ERBB2
19
Show member pathways
12.68 TP53 PTEN PIK3CA KRAS HRAS ESR1
20
Show member pathways
12.67 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
21
Show member pathways
12.65 TP53 PTEN PIK3CA KRAS HRAS ESR1
22 12.61 TP53 PTEN PIK3CA KRAS HRAS ERBB2
23
Show member pathways
12.58 TP53 PTEN PIK3CA KRAS HRAS ERBB2
24 12.58 TP53 PTEN PIK3CA KRAS KIT HRAS
25
Show member pathways
12.56 PTEN PIK3CA KRAS HRAS ESR1 ERBB2
26
Show member pathways
12.56 TP53 PTEN PIK3CA KRAS HRAS CTNNB1
27
Show member pathways
12.52 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
28
Show member pathways
12.47 PIK3CA KRAS HRAS ESR1 CTNNB1
29
Show member pathways
12.46 PIK3CA KRAS KIT HRAS ERBB2 CTNNB1
30
Show member pathways
12.41 PPP2R1A PIK3CA PGR KRAS
31 12.41 TP53 PTEN PIK3CA KRAS HRAS
32
Show member pathways
12.41 PIK3CA KRAS HRAS ERBB2 CTNNB1 CDH1
33
Show member pathways
12.4 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
34
Show member pathways
12.37 PIK3CA HRAS ESR1 ERBB2
35 12.35 TP53 PIK3CA KRAS HRAS
36
Show member pathways
12.34 PIK3CA KRAS HRAS ERBB2
37
Show member pathways
12.32 PPP2R1A PIK3CA KRAS HRAS
38
Show member pathways
12.32 TP53 PTEN PIK3CA KRAS HRAS ERBB2
39 12.29 TP53 PIK3CA KRAS HRAS ESR1 ERBB2
40 12.24 TP53 KRAS CTNNB1 CDH1
41 12.24 PTEN KRAS HRAS ERBB2
42 12.24 TP53 PTEN PIK3CA KRAS HRAS
43
Show member pathways
12.23 TP53 PIK3CA KRAS HRAS
44
Show member pathways
12.22 PTEN PIK3CA KIT HRAS
45
Show member pathways
12.22 PTEN PIK3CA KRAS HRAS ERBB2
46 12.22 TP53 PTEN KRAS ESR1 CTNNB1 CDH1
47
Show member pathways
12.19 TP53 PIK3CA KRAS HRAS
48 12.16 PIK3CA KRAS HRAS CTNNB1
49
Show member pathways
12.14 PTEN PIK3CA KRAS HRAS
50 12.14 PTEN PIK3CA KRAS HRAS

GO Terms for Mixed Cell Type Cancer

Cellular components related to Mixed Cell Type Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perinuclear region of cytoplasm GO:0048471 9.63 SYP PIK3CA HRAS ERBB2 CTNNB1 CDH1
2 lateral plasma membrane GO:0016328 9.5 PPP2R1A CTNNB1 CDH1
3 cytoplasm GO:0005737 9.5 TP53 PTEN PPP2R1A PIK3CA PGR MME
4 flotillin complex GO:0016600 9.26 CTNNB1 CDH1
5 cytoplasmic side of plasma membrane GO:0009898 9.13 PTEN KIT CDH1

Biological processes related to Mixed Cell Type Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription by RNA polymerase II GO:0006357 10.14 TP53 PGR LCOR KIT ESR1 ERBB2
2 positive regulation of cell proliferation GO:0008284 9.88 PTEN KRAS KIT HRAS ERBB2 CTNNB1
3 negative regulation of gene expression GO:0010629 9.83 TP53 PGR HRAS ESR1 CTNNB1
4 positive regulation of protein kinase B signaling GO:0051897 9.8 PIK3CA KIT ESR1 ERBB2
5 Ras protein signal transduction GO:0007265 9.72 TP53 KRAS HRAS
6 positive regulation of MAPK cascade GO:0043410 9.67 KIT HRAS ERBB2 CTNNB1
7 phosphatidylinositol 3-kinase signaling GO:0014065 9.63 PTEN PIK3CA ERBB2
8 positive regulation of DNA-binding transcription factor activity GO:0051091 9.62 PTEN KIT ESR1 CTNNB1
9 response to isolation stress GO:0035900 9.52 KRAS HRAS
10 entry of bacterium into host cell GO:0035635 9.51 CTNNB1 CDH1
11 cellular response to indole-3-methanol GO:0071681 9.48 CTNNB1 CDH1
12 regulation of long-term neuronal synaptic plasticity GO:0048169 9.43 SYP KRAS HRAS
13 positive regulation of phospholipase C activity GO:0010863 9.33 KIT HRAS ESR1
14 positive regulation of MAP kinase activity GO:0043406 9.26 KRAS KIT HRAS ERBB2
15 positive regulation of gene expression GO:0010628 9.17 TP53 PTEN KRAS KIT HRAS ERBB2

Molecular functions related to Mixed Cell Type Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.86 TP53 SYP PTEN PGR KRAS ESR1
2 protein binding GO:0005515 9.62 TP53 SYP SERPINA3 PTEN PPP2R1A PIK3CA
3 enzyme binding GO:0019899 9.55 TP53 PTEN PGR ESR1 CTNNB1
4 estrogen receptor binding GO:0030331 9.13 LCOR ESR1 CTNNB1

Sources for Mixed Cell Type Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....